Long term efficacy of first-line afatinib and the clinical utility of ctDNA monitoring in patients with suspected or confirmed EGFR mutant non-small cell lung cancer who were unsuitable for chemotherapy.
No Thumbnail Available
All Authors
Popat, S.
Januszewski, A.
O'Brien, M.
Ahmad, T.
Lewanski, C.
Dernedde, U.
Jankowska, P.
Mulatero, C.
Shah, R.
Hicks, J.
LTHT Author
Mulatero, Clive
LTHT Department
Oncology
Non Medic
Publication Date
2025
Item Type
Journal Article
Clinical Trial, Phase II
Multicenter Study
Clinical Trial, Phase II
Multicenter Study
Language
Subject
Subject Headings
Abstract
BACKGROUND: Here we present long-term outcomes of first line afatinib in comorbid patients with suspected or confirmed EGFR mutant NSCLC otherwise considered unsuitable for chemotherapy, and the clinical utility of serial ctDNA monitoring.
METHODS: TIMELY (NCT01415011) was a multicentre, single arm, phase II trial conducted in the UK. Patients aged >=18 were treated with daily oral afatinib (40 mg) until disease progression or unacceptable toxicity. Blood samples for ctDNA analysis were obtained at baseline and 12-weekly until treatment discontinuation. The primary endpoint was PFS.
RESULTS: Thirty-nine patients were enrolled between March 2013 and August 2015. Median follow-up was 98 months (range 69-101). Median PFS was 7.9 months (95% CI 4.6-10.5). Seven patients (18%) continued afatinib beyond 18 months, 3 beyond 36 months and 2 were still on treatment at last follow-up 101 months post-treatment initiation. Analysis of baseline ctDNA samples identified 8 EGFR mutant cases that were not identified by tissue genotyping and ctDNA clearance was associated with improved PFS and OS.
CONCLUSION: Afatinib is a viable treatment option for tissue or ctDNA-detected EGFR mutant NSCLC comorbid patients, with a proportion achieving long-term clinical benefit. Plasma ctDNA testing improved EGFR mutant identification and its clearance predicted improved PFS and OS.
Journal
British Journal of Cancer